Working... Menu

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02665650
Recruitment Status : Completed
First Posted : January 28, 2016
Last Update Posted : May 16, 2019
Merck Sharp & Dohme Corp.
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Affimed GmbH

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2019
  Actual Study Completion Date : March 2019